Drugs / SONEDENOSON
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00318214 | Jun 2006 → Feb 2008 | ulcer of lower limbs | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00312364 | Dec 2005 → Dec 2007 | ulcer of lower limbs | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SONEDENOSON | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950553 ↗ |
| Known as | MRE0094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00312364 ↗ |
| Action | Activate | “Adenosine A2a receptor agonist” CHEMBL1950553 ↗ |
| Modality | Small molecule | — CHEMBL1950553 ↗ |
| Route | Topical | “This is a clinical research study of an experimental topical drug for the treatment of chronic, neuropathic, diabetic foot ulcers.” NCT00312364 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor agonist” CHEMBL1950553 ↗ |